Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Nokia and Cinia partner to secure Finland’s critical infrastructure with advanced DDoS protection Cinia deploying Nokia advanced Distributed Denial of Service (DDoS) protection solution to safeguard...
-
Greywolf Therapeutics appoints renowned biotech entrepreneur Dr Edwin Moses as Chair, bringing 30+ years of life sciences leadership
-
Bang & Olufsen generated 1% revenue growth in local currencies for the quarter, which was lower than expected. The gross margin continued its solid trajectory and was 57.5%, an increase of 2.1...
-
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....
-
Pluxee affiche une forte progression de sa rentabilité et de sa génération de trésorerie au premier semestre 2026 et confirme l’ensemble de ses objectifs annuels Faits marquants Performance...
-
Pluxee delivers strong margin expansion and cash generation in H1 Fiscal 2026, reaffirming all full‑year objectives Highlights Robust commercial traction in H1 Fiscal 2026 on track with full-year...
-
Strong start of the year with Q1 2026 revenueup +13.6% in constant currencies Revenue reaching € 51.0 million; +13.6% in constant currencies, in line with FY planned trajectorySolid commercial...
-
Uitbreiding van de portefeuille levert verwachte performantie
-
Portfolio expansion delivers expected performance
-
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
BASEL, Switzerland, April 16, 2026 (GLOBE NEWSWIRE) -- BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated...